Total Payments
$528,983
2020 Payments
$4,179
Companies
10
Transactions
493
Payment Breakdown by Category
Other$289,948 (54.8%)
Consulting$140,184 (26.5%)
Travel$70,000 (13.2%)
Research$20,178 (3.8%)
Food & Beverage$8,672 (1.6%)
Education$2.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $265,263 | 76 | 50.1% |
| Consulting Fee | $140,184 | 39 | 26.5% |
| Travel and Lodging | $70,000 | 204 | 13.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $24,685 | 6 | 4.7% |
| Unspecified | $20,178 | 23 | 3.8% |
| Food and Beverage | $8,672 | 144 | 1.6% |
| Education | $2.50 | 1 | 0.0% |
Payments by Type
General
$508,805
470 transactions
Research
$20,178
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $128,504 | 132 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $97,791 | 72 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $90,451 | 101 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $78,275 | 61 | $0 (2019) |
| GENZYME CORPORATION | $59,071 | 44 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $58,692 | 68 | $0 (2020) |
| Amgen Inc. | $15,905 | 11 | $0 (2019) |
| Biocompatibles, Inc. | $164.14 | 1 | $0 (2018) |
| Genentech USA, Inc. | $108.75 | 2 | $0 (2017) |
| Eisai Inc. | $21.63 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $4,179 | 9 | Regeneron Pharmaceuticals, Inc. ($4,179) |
| 2019 | $264,545 | 196 | Regeneron Healthcare Solutions, Inc. ($71,436) |
| 2018 | $173,031 | 174 | E.R. Squibb & Sons, L.L.C. ($40,884) |
| 2017 | $87,228 | 114 | E.R. Squibb & Sons, L.L.C. ($38,707) |
All Payment Transactions
493 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/14/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $1,113.63 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/14/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $972.72 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/04/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $385.41 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/17/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $122.33 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/06/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $117.42 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/25/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $112.14 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/17/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $1,123.21 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/17/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $116.74 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/17/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $115.40 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/12/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $30.55 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 11/27/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 11/18/2019 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,505.00 | General |
| 11/15/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,540.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $30.55 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 11/12/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 11/12/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,230.00 | General |
| Category: Oncology | ||||||
| 11/07/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $117.01 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 11/05/2019 | Amgen Inc. | IMLYGIC (Biological) | — | In-kind items and services | $7,056.61 | Research |
| Study: Treatment Patterns Among Patients with Malignant Melanoma in MarketScan claims data 2011- 2016 • Category: Oncology | ||||||
| 11/04/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $697.30 | General |
| Category: Oncology | ||||||
| 11/04/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $190.02 | General |
| Category: Oncology | ||||||
| 10/30/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $1,070.83 | General |
| Category: Oncology | ||||||
| 10/30/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $112.28 | General |
| Category: Oncology | ||||||
| 10/29/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $228.38 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 10/28/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Oncology | ||||||
| 10/28/2019 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $400.95 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Treatment Patterns Among Patients with Malignant Melanoma in MarketScan claims data 2011- 2016 | Amgen Inc. | $14,037 | 2 |
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $4,179 | 9 |
| Systematic literature review and comparative efficacy of cemiplimab versus systemic treatments for advanced cutaneous squamous cell carcinoma | GENZYME CORPORATION | $1,136 | 3 |
| Libtayo Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $826.83 | 9 |
About Dr. Morganna Freeman, D.O
Dr. Morganna Freeman, D.O is a Medical Oncology healthcare provider based in Glendale, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2009. The National Provider Identifier (NPI) number assigned to this provider is 1730314345.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Morganna Freeman, D.O has received a total of $528,983 in payments from pharmaceutical and medical device companies, with $4,179 received in 2020. These payments were reported across 493 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($265,263).
Ad
Practice Information
- Specialty Medical Oncology
- Location Glendale, CA
- Active Since 05/27/2009
- Last Updated 08/27/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1730314345
Products in Payments
- LIBTAYO (Biological) $97,620
- OPDIVO (Biological) $91,443
- MEKINIST (Drug) $73,894
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $57,682
- KEYTRUDA (Biological) $55,648
- LIBTAYO (Drug) $52,356
- IMLYGIC (Biological) $15,079
- NO PRODUCT DISCUSSED (Drug) $6,715
- TAFINLAR (Drug) $2,987
- THERASPHERE - BIO (Device) $164.14
- COTELLIC (Drug) $56.72
- Zelboraf (Biological) $52.03
- Vectibix (Biological) $48.96
- Lenvima (Drug) $21.63
- BINIMETINIB (Drug) $12.50
- KISQALI (Drug) $10.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Glendale
Raymundo Romero, M.d, M.D
Medical Oncology — Payments: $39,360
Medical Oncology $39,360
Dr. James Ewing, M.d, M.D
Medical Oncology — Payments: $38,980
Medical Oncology $38,980
Dr. Demetrio Mamani, M.d, M.D
Medical Oncology — Payments: $10,968
Medical Oncology $10,968
Lamia Boric, M.d, M.D
Medical Oncology — Payments: $1,222
Medical Oncology $1,222